- Home
- PRO vs ETNB Comparison
PRO vs ETNB Comparison
Compare PRO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- ETNB
- Stock Information
- Founded
- PRO 1985
- ETNB 2018
- Country
- PRO United States
- ETNB United States
- Employees
- PRO N/A
- ETNB N/A
- Industry
- PRO EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PRO Technology
- ETNB Health Care
- Exchange
- PRO Nasdaq
- ETNB Nasdaq
- Market Cap
- PRO 1.1B
- ETNB 867.4M
- IPO Year
- PRO 2007
- ETNB 2019
- Fundamental
- Price
- PRO $23.62
- ETNB $8.38
- Analyst Decision
- PRO Strong Buy
- ETNB Buy
- Analyst Count
- PRO 8
- ETNB 7
- Target Price
- PRO $31.63
- ETNB $30.33
- AVG Volume (30 Days)
- PRO 620.3K
- ETNB 999.8K
- Earning Date
- PRO 10-29-2024
- ETNB 11-07-2024
- Dividend Yield
- PRO N/A
- ETNB N/A
- EPS Growth
- PRO N/A
- ETNB N/A
- EPS
- PRO N/A
- ETNB N/A
- Revenue
- PRO $322,887,000.00
- ETNB N/A
- Revenue This Year
- PRO $9.81
- ETNB N/A
- Revenue Next Year
- PRO $9.37
- ETNB $133.30
- P/E Ratio
- PRO N/A
- ETNB N/A
- Revenue Growth
- PRO 8.66
- ETNB N/A
- 52 Week Low
- PRO $16.64
- ETNB $7.00
- 52 Week High
- PRO $40.99
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- PRO 64.93
- ETNB 48.14
- Support Level
- PRO $21.40
- ETNB $7.68
- Resistance Level
- PRO $23.69
- ETNB $10.01
- Average True Range (ATR)
- PRO 1.01
- ETNB 0.73
- MACD
- PRO 0.00
- ETNB -0.17
- Stochastic Oscillator
- PRO 88.09
- ETNB 23.15
About PRO PROS Holdings Inc.
Pros Holdings Inc. is a provider of cloud-based revenue and profit realization software solutions to business-to-business and business-to-consumer companies. Its solutions assist customers in growing revenue, modernizing business processes, and supporting profitability by leveraging prescriptive analytics and data science-based decision-making technology. The company's solutions enable buyers to move fluidly across its customers' direct sales, partner, online, mobile, and emerging channels with personalized experiences. The firm generates revenue in the United States, Europe, Africa, Asia-Pacific, and Middle East regions.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).